Last reviewed · How we verify
T-Pred
T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system.
T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system. Used for Treatment of inflammation and pain in the eye.
At a glance
| Generic name | T-Pred |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
T-Pred works by inhibiting the production of inflammatory chemicals in the body, which helps to reduce swelling and alleviate symptoms associated with various conditions. It is a type of glucocorticoid, which is a class of steroid hormones that play a crucial role in regulating the immune response.
Approved indications
- Treatment of inflammation and pain in the eye
Common side effects
- Increased intraocular pressure
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (PHASE1, PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-Pred CI brief — competitive landscape report
- T-Pred updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI